Identification and Characterization of Human Proteoforms by Top-Down LC-21 Tesla FT-ICR Mass Spectrometry.
Lissa C AndersonCaroline J DeHartNathan K KaiserRyan T FellersDonald F SmithJoseph B GreerRichard D LeDucGreg T BlakneyPaul M ThomasMichael P SnyderChristopher L HendricksonPublished in: Journal of proteome research (2016)
Successful high-throughput characterization of intact proteins from complex biological samples by mass spectrometry requires instrumentation capable of high mass resolving power, mass accuracy, sensitivity, and spectral acquisition rate. These limitations often necessitate the performance of hundreds of LC-MS/MS experiments to obtain reasonable coverage of the targeted proteome, which is still typically limited to molecular weights below 30 kDa. The National High Magnetic Field Laboratory (NHMFL) recently installed a 21 T FT-ICR mass spectrometer, which is part of the NHMFL FT-ICR User Facility and available to all qualified users. Here we demonstrate top-down LC-21 T FT-ICR MS/MS of intact proteins derived from human colorectal cancer cell lysate. We identified a combined total of 684 unique protein entries observed as 3238 unique proteoforms at a 1% false discovery rate, based on rapid, data-dependent acquisition of collision-induced and electron-transfer dissociation tandem mass spectra from just 40 LC-MS/MS experiments. Our identifications included 372 proteoforms with molecular weights over 30 kDa detected at isotopic resolution, which substantially extends the accessible mass range for high-throughput top-down LC-MS/MS.
Keyphrases
- high throughput
- mass spectrometry
- endothelial cells
- liquid chromatography
- ms ms
- electron transfer
- high resolution
- induced pluripotent stem cells
- single molecule
- high performance liquid chromatography
- simultaneous determination
- heat shock protein
- high glucose
- healthcare
- magnetic resonance imaging
- capillary electrophoresis
- diabetic rats
- electronic health record
- drug induced
- cancer therapy
- deep learning
- affordable care act
- solid phase extraction
- binding protein
- contrast enhanced